-
Product Insights
NewNet Present Value Model: Alaunos Therapeutics Inc’s Gene Therapy 2 for Oncology
Empower your strategies with our Net Present Value Model: Alaunos Therapeutics Inc's Gene Therapy 2 for Oncology report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Alaunos Therapeutics Inc’s Gene-Modified Cell Therapy to Target CD56 for Oncology
Empower your strategies with our Net Present Value Model: Alaunos Therapeutics Inc's Gene-Modified Cell Therapy to Target CD56 for Oncology report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Alaunos Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Alaunos Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
NewRare Disease ​Pipeline Analysis ​Landscape, 2023
This report investigates the Rare Disease ​Pipeline Analysis ​Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy 2 For Oncology in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 2 For Oncology in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy 2 For Oncology in Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy 2 For Oncology in Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 2 For Oncology in Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy 2 For Oncology in Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone in Migraine
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone in Migraine Drug Details: Naltrexone is under development for the treatment of postherpetic neuralgia,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target CD19 For B-Cell Malignancies in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD19 For B-Cell Malignancies in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TCR-T Library in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TCR-T Library in Lung Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TCR-T Library in Lung Adenocarcinoma Drug Details: Gene-modified cell therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TCR-T Library in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TCR-T Library in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TCR-T Library in Ovarian Cancer Drug Details: Gene-modified cell therapy...